Abstract
Objective Metformin is one of the most used drugs worldwide. However, its mechanism of action remains uncertain. Given the potential to reveal novel insights into the pleiotropic effects of metformin treatment, we aimed to undertake a comprehensive analysis of circulating proteins.
Research Design and Methods We analysed 1195 proteins using the SomaLogic platform in 1175 participants, using cross- sectional data from the GoDARTS and DCS cohorts; 450 proteins using the Olink platform in 784 participants, using cross-sectional data from IMI-DIRECT; and combined longitudinal data from the IMPOCT, RAMP and S3WP-T2D cohorts with 372 proteins in 98 participants using the Olink platform. Finally, we performed systems level analysis on the longitudinal OLINK data to identify any possible relationships for the proteins changing concentration following metformin exposure.
Results Overall, 97 proteins were associated with metformin exposure in at least one of the studies (Padj<0.05), and 10 proteins (EpCAM, SPINK1, t-PA, Gal-4, TFF3, TF, FAM3C, COL1A1, SELL, CD93) were associated in two independent studies. Four proteins, REG4, GDF15, REG1A, and OMD were consistently associated across all studies and platforms. Gene-set enrichment analysis revealed that the effect of metformin exposure was on intestinal tissues. In the longitudinal analysis 18% of proteins were significantly altered by metformin.
Conclusions These data provide further insight into the mechanism of action of metformin, potentially identifying novel targets for diabetes treatment, and highlight the need to account for metformin exposure in proteomic studies and where protein biomarkers are used for clinical care where metformin treatment will generate false positive results.
Highlights
In the most comprehensive proteomic analysis of metformin exposure to date, we showed 97 proteins to be associated with metformin exposure in at least one study.
14 proteins were consistently associated with metformin exposure in 2 or more platforms or studies.
Gene enrichment analysis shows that the strongest protein set is of intestinal origin.
These data provide further insight into the mechanism of action of metformin, potentially identify novel targets for diabetes treatment and highlight the need to account for metformin exposure in proteomic studies and where protein biomarkers are used for clinical care.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02586636 NCT02733679
Funding Statement
This study was funded by the innovative medicines initiative.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
GoDARTS The study was approved by the East of Scotland Research Ethics Service, reference 09/S1402/44 DCS The study has been approved by the ethics committee of the Amsterdam University Medical Center, location VUmc (approval number 2007/57; NL14692.029.07) DIRECT The UK National Research Ethics Service (NRES) Committee North East Newcastle & North Tyneside gave ethical approval for this work under REC reference 12/NE/0132, Protocol Number 2011DIRECT02 in May 2012. IMPOCT East of Scotland Research Ethics Service gave University of Dundee ethical approval for this work, REC reference: 15/ES/0189 RAMP East of Scotland Research Ethics Service gave University of Dundee ethical approval for this work, REC reference: 16/ES/0056 S3WPT2D The Ethical Review Board in Gothenburg gave ethical approval for this work (Dnr 448-16).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
